Stockscreener 앱 받기
0.2765
4.82%
0.0149
전일 마감가:
$0.2616
열려 있는:
$0.273
하루 거래량:
206.12K
Relative Volume:
0.17
시가총액:
$16.81M
수익:
$1.16M
순이익/손실:
$-39.74M
주가수익비율:
-0.446
EPS:
-0.62
순현금흐름:
$-35.02M
1주 성능:
+5.26%
1개월 성능:
+52.33%
6개월 성능:
-29.69%
1년 성능:
-85.02%
1일 변동 폭
$0.2655
$0.2877
1주일 범위
$0.2275
$0.2877
52주 변동 폭
$0.1406
$0.63
Glycomimetics Inc Stock (GLYC) Company Profile
명칭
Glycomimetics Inc
전화
240-243-1201
주소
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
GLYC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLYC
Glycomimetics Inc
|
0.2765 | 16.81M | 1.16M | -39.74M | -35.02M | -0.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.35 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.33 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.60 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.24 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.43 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-26 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-22 | 개시 | CapitalOne | Overweight |
| 2021-11-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-05 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2018-12-18 | 개시 | H.C. Wainwright | Buy |
| 2016-07-26 | 개시 | SunTrust | Buy |
| 2015-03-17 | 재확인 | Stifel | Buy |
모두보기
Glycomimetics Inc 주식(GLYC)의 최신 뉴스
A Stock Analysis Of GlycoMimetics Inc’s (GLYC) - Stocksregister
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com - Defense World
Ratios Revealed: Decoding GlycoMimetics Inc (GLYC)’s Financial Health - DWinneX
GlycoMimetics Inc (GLYC Stock: A Sea of Opportunity - investchronicle.com
Cantor Fitzgerald initates GlycoMimetics Inc (GLYC) rating to an Overweight - knoxdaily.com
GlycoMimetics Amends Merger Agreement With Crescent Biopharma - Investing.com
GlycoMimetics, Inc. (GLYC) Stock Report: Analyst Ratings Signal Potential in Biotech Space - DirectorsTalk Interviews
Press Release Distribution & PR Platform - ACCESS Newswire
A Look at GlycoMimetics Inc (GLYC) Shares in the Recent Past Indicates Growth - Sete News
GLYC Shares Experience Surge in Value - knoxdaily.com
GlycoMimetics (NASDAQ:GLYC) Stock Price Passes Below 200 Day Moving Average – Time to Sell? - Defense World
GlycoMimetics Inc (GLYC) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Understanding GLYC stock ratios for better investment decisions - uspostnews.com
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World
Wellington Management Group LLP Makes New Investment in GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics, Inc. Announces Efficacy and Safety Data from Phase 1/2 Clinical Study of Uproleselan Published in BLOOD - MarketScreener
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com - Defense World
Form 425 GLYCOMIMETICS INC Filed by: GLYCOMIMETICS INC - StreetInsider
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - Quantisnow
GLYCOMIMETICS Earnings Preview: Recent $GLYC Insider Trading, Hedge Fund Activity, and More - Nasdaq
Cantor Fitzgerald Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
Cantor Fitzgerald maintains Overweight on GlycoMimetics stock By Investing.com - Investing.com Australia
Cantor Fitzgerald Initiates Coverage of GlycoMimetics (GLYC) with Overweight Recommendation - MSN
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated by Analysts at StockNews.com - Defense World
Cantor Fitzgerald maintains Overweight on GlycoMimetics stock - Investing.com India
Cantor Fitzgerald Initiates GlycoMimetics at Overweight -March 21, 2025 at 07:18 am EDT - Marketscreener.com
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
GlycoMimetics, Inc. (NASDAQ:GLYC) Short Interest Update - Defense World
StockNews.com Initiates Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics, Inc. to Host Earnings Call - ACCESS Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders - The Malaysian Reserve
GlycoMimetics, Inc. Announces Board Resignations -February 25, 2025 at 05:00 pm EST - Marketscreener.com
GlycoMimetics Says Following Termination, Co Will Not Have Any Material Financial Or Other Obligations Under Agreement - TradingView
GlycoMimetics ends key agreement; board members, executives depart By Investing.com - Investing.com South Africa
GlycoMimetics ends key agreement; board members, executives depart - Investing.com
GlycoMimetics Faces Leadership Changes Amid Board Resignations - TipRanks
US Penny Stocks To Watch In February 2025 - Yahoo Finance
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week - NewsBreak
GlycoMimetics adjusts merger terms with Crescent Biopharma - MSN
GlycoMimetics And GENFIT Announce Significant Agreement Amendments - Evrim Ağacı
Glycomimetics Inc (GLYC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Glycomimetics Inc 주식 (GLYC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10% Owner |
Aug 07 '24 |
Sale |
0.18 |
61,488 |
11,197 |
6,578,438 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 05 '24 |
Sale |
0.19 |
164,523 |
30,996 |
6,695,658 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 06 '24 |
Sale |
0.18 |
55,732 |
10,188 |
6,639,926 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 02 '24 |
Sale |
0.20 |
286,200 |
57,354 |
6,860,181 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 01 '24 |
Sale |
0.22 |
63,564 |
13,743 |
7,146,381 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 30 '24 |
Sale |
0.22 |
756,835 |
167,185 |
7,209,945 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 29 '24 |
Sale |
0.24 |
363,949 |
85,637 |
7,966,780 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 26 '24 |
Sale |
0.24 |
258,335 |
62,440 |
8,330,729 |
| Rock Edwin | Chief Medical Officer |
Jun 20 '24 |
Buy |
0.25 |
190,000 |
48,108 |
565,403 |
| Rock Edwin | Chief Medical Officer |
Jun 21 '24 |
Buy |
0.27 |
115,000 |
30,716 |
680,403 |
0.52%
0.52%
자본화:
|
볼륨(24시간):